Waleed Arafat, Professor of Clinical Oncology at University of Alexandria, shared a post on LinkedIn by David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, adding:
“Antibody–drug conjugates (ADCs) have become key players across oncology. China is emerging as a leader in this space. The concept is relatively straightforward, cost-effective, and accessible to design, making it a promising area for scientists in low- and middle-income countries to invest in.”
Quoting David Planchard’s post:
“Great EGFR-mutant NSCLC session. Impressed by the Sac-TMT results (anti-TROP2 ADC), which show the most positive outcomes across two Chinese studies.
Other ADCs are also in the pipeline, things are really moving for the post-Osimertinib +/- chemo setting.”
